IN2014MN02156A - - Google Patents
Info
- Publication number
- IN2014MN02156A IN2014MN02156A IN2156MUN2014A IN2014MN02156A IN 2014MN02156 A IN2014MN02156 A IN 2014MN02156A IN 2156MUN2014 A IN2156MUN2014 A IN 2156MUN2014A IN 2014MN02156 A IN2014MN02156 A IN 2014MN02156A
- Authority
- IN
- India
- Prior art keywords
- acid
- microparticles
- alfentanil
- presented
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1207701.2A GB201207701D0 (en) | 2012-05-02 | 2012-05-02 | New pharmaceutical composition |
| GBGB1221130.6A GB201221130D0 (en) | 2012-11-23 | 2012-11-23 | New pharmaceutical composition |
| PCT/GB2013/051131 WO2013164620A1 (en) | 2012-05-02 | 2013-05-01 | New alfentanil composition for the treatment of acute pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02156A true IN2014MN02156A (xx) | 2015-08-28 |
Family
ID=48577134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2156MUN2014 IN2014MN02156A (xx) | 2012-05-02 | 2013-05-01 |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US8815911B2 (xx) |
| EP (2) | EP3150199B1 (xx) |
| JP (1) | JP6275696B2 (xx) |
| KR (1) | KR20150005695A (xx) |
| CN (1) | CN104427978B (xx) |
| AU (1) | AU2013255640B2 (xx) |
| BR (1) | BR112014027213A8 (xx) |
| CA (1) | CA2871805A1 (xx) |
| CL (1) | CL2014002979A1 (xx) |
| CO (1) | CO7170181A2 (xx) |
| CY (2) | CY1118570T1 (xx) |
| DK (2) | DK3150199T3 (xx) |
| EA (1) | EA028110B1 (xx) |
| ES (2) | ES2614757T3 (xx) |
| HK (1) | HK1203399A1 (xx) |
| HR (2) | HRP20161634T1 (xx) |
| HU (1) | HUE031792T2 (xx) |
| IL (1) | IL235272B (xx) |
| IN (1) | IN2014MN02156A (xx) |
| LT (2) | LT2849730T (xx) |
| ME (1) | ME02644B (xx) |
| MX (1) | MX360665B (xx) |
| NZ (1) | NZ701428A (xx) |
| PE (1) | PE20142444A1 (xx) |
| PH (1) | PH12014502407B1 (xx) |
| PL (2) | PL3150199T3 (xx) |
| PT (2) | PT2849730T (xx) |
| RS (2) | RS55489B1 (xx) |
| SG (1) | SG11201407081PA (xx) |
| SI (2) | SI3150199T1 (xx) |
| SM (1) | SMT201700086B (xx) |
| TR (1) | TR201815935T4 (xx) |
| WO (1) | WO2013164620A1 (xx) |
| ZA (1) | ZA201407559B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103813785B (zh) | 2011-09-19 | 2017-02-15 | 奥瑞克索股份公司 | 新的治疗阿片样物质依赖的抗滥用药物组合物 |
| PL3150199T3 (pl) * | 2012-05-02 | 2019-03-29 | Orexo Ab | Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu |
| WO2017180659A1 (en) * | 2016-04-11 | 2017-10-19 | Arizona Board Of Regents On Behalf Of University Of Arizona | Opioid receptor modulators |
| JP7023054B2 (ja) * | 2017-04-05 | 2022-02-21 | 東和薬品株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| DE19758564A1 (de) | 1997-11-11 | 1999-08-26 | Gruenenthal Gmbh | Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9904911D0 (en) | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20020160043A1 (en) | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| JP4850346B2 (ja) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
| US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20060216352A1 (en) | 2003-01-31 | 2006-09-28 | Orexo Ab | Rapid-acting pharmaceutical composition |
| ES2414084T3 (es) | 2003-02-24 | 2013-07-18 | Pharmaceutical Productions Inc. | Sistema de administración de fármacos por vía transmucosa |
| US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| CA2549642C (en) | 2003-12-31 | 2012-10-30 | Cima Labs Inc. | Effervescent oral opiate dosage forms and methods of administering opiates |
| NZ548216A (en) | 2003-12-31 | 2010-02-26 | Cima Labs Inc | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| US20070036853A1 (en) | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| WO2005065317A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| US20080248110A1 (en) | 2005-03-28 | 2008-10-09 | Anders Pettersson | Pharmaceutical Compositions Useful in the Treatment of Pain |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| US8535714B2 (en) * | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) * | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US20100233257A1 (en) | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
| US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
| NZ594545A (en) * | 2006-07-21 | 2012-12-21 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with enhanced uptake containing fentanyl or buprenorphine |
| DK2101740T3 (da) * | 2006-12-04 | 2013-11-18 | Orexo Ab | Nye ikke-misbrugs-farmaceutiske sammensætninger omfattende opioider |
| EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| JP5632284B2 (ja) | 2007-08-07 | 2014-11-26 | エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド | 経口経粘膜剤形を使用する処置時の鎮静および無痛のための組成物および方法 |
| US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
| US8343978B2 (en) | 2008-08-04 | 2013-01-01 | Adds Pharmaceuticals Llc | Fast onset orodispersable tablets |
| WO2010027770A1 (en) | 2008-09-04 | 2010-03-11 | Mallinckrodt Inc. | Crystalline forms of sufentanil citrate |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| EP2429503A1 (en) | 2009-05-13 | 2012-03-21 | Protein Delivery Solutions, LLC | Pharmaceutical system for trans-membrane delivery |
| WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
| JP2009280611A (ja) * | 2009-08-26 | 2009-12-03 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜フィルム剤 |
| US20110091544A1 (en) | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| US20110150989A1 (en) | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| PL3150199T3 (pl) * | 2012-05-02 | 2019-03-29 | Orexo Ab | Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu |
-
2013
- 2013-05-01 PL PL16197166T patent/PL3150199T3/pl unknown
- 2013-05-01 BR BR112014027213A patent/BR112014027213A8/pt not_active Application Discontinuation
- 2013-05-01 PT PT137273140T patent/PT2849730T/pt unknown
- 2013-05-01 SI SI201331238T patent/SI3150199T1/sl unknown
- 2013-05-01 CA CA2871805A patent/CA2871805A1/en not_active Abandoned
- 2013-05-01 LT LTEP13727314.0T patent/LT2849730T/lt unknown
- 2013-05-01 DK DK16197166.8T patent/DK3150199T3/en active
- 2013-05-01 MX MX2014013176A patent/MX360665B/es active IP Right Grant
- 2013-05-01 EA EA201401200A patent/EA028110B1/ru not_active IP Right Cessation
- 2013-05-01 EP EP16197166.8A patent/EP3150199B1/en active Active
- 2013-05-01 US US13/874,762 patent/US8815911B2/en not_active Expired - Fee Related
- 2013-05-01 EP EP13727314.0A patent/EP2849730B1/en active Active
- 2013-05-01 ES ES13727314.0T patent/ES2614757T3/es active Active
- 2013-05-01 JP JP2015509496A patent/JP6275696B2/ja not_active Expired - Fee Related
- 2013-05-01 ES ES16197166.8T patent/ES2694644T3/es active Active
- 2013-05-01 NZ NZ701428A patent/NZ701428A/en not_active IP Right Cessation
- 2013-05-01 AU AU2013255640A patent/AU2013255640B2/en not_active Ceased
- 2013-05-01 LT LTEP16197166.8T patent/LT3150199T/lt unknown
- 2013-05-01 HU HUE13727314A patent/HUE031792T2/en unknown
- 2013-05-01 DK DK13727314.0T patent/DK2849730T3/en active
- 2013-05-01 KR KR1020147033700A patent/KR20150005695A/ko not_active Application Discontinuation
- 2013-05-01 PT PT16197166T patent/PT3150199T/pt unknown
- 2013-05-01 SI SI201330490A patent/SI2849730T1/sl unknown
- 2013-05-01 SG SG11201407081PA patent/SG11201407081PA/en unknown
- 2013-05-01 RS RS20161161A patent/RS55489B1/sr unknown
- 2013-05-01 CN CN201380022630.2A patent/CN104427978B/zh not_active Expired - Fee Related
- 2013-05-01 IN IN2156MUN2014 patent/IN2014MN02156A/en unknown
- 2013-05-01 ME MEP-2017-9A patent/ME02644B/me unknown
- 2013-05-01 WO PCT/GB2013/051131 patent/WO2013164620A1/en active Application Filing
- 2013-05-01 PL PL13727314T patent/PL2849730T3/pl unknown
- 2013-05-01 RS RS20181295A patent/RS57951B1/sr unknown
- 2013-05-01 PE PE2014001937A patent/PE20142444A1/es not_active Application Discontinuation
- 2013-05-01 TR TR2018/15935T patent/TR201815935T4/tr unknown
-
2014
- 2014-07-15 US US14/331,507 patent/US9345698B2/en not_active Expired - Fee Related
- 2014-10-17 ZA ZA2014/07559A patent/ZA201407559B/en unknown
- 2014-10-22 IL IL235272A patent/IL235272B/en not_active IP Right Cessation
- 2014-10-27 PH PH12014502407A patent/PH12014502407B1/en unknown
- 2014-10-29 CO CO14239767A patent/CO7170181A2/es not_active Application Discontinuation
- 2014-11-03 CL CL2014002979A patent/CL2014002979A1/es unknown
-
2015
- 2015-04-28 HK HK15104088.8A patent/HK1203399A1/xx not_active IP Right Cessation
-
2016
- 2016-04-26 US US15/138,570 patent/US9782396B2/en not_active Expired - Fee Related
- 2016-12-05 HR HRP20161634TT patent/HRP20161634T1/hr unknown
-
2017
- 2017-01-31 CY CY20171100139T patent/CY1118570T1/el unknown
- 2017-02-08 SM SM201700086T patent/SMT201700086B/it unknown
- 2017-09-11 US US15/701,300 patent/US20180214437A1/en not_active Abandoned
-
2018
- 2018-10-25 HR HRP20181761TT patent/HRP20181761T1/hr unknown
- 2018-11-05 CY CY181101154T patent/CY1120820T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| PH12015502002A1 (en) | Tripeptide epoxy ketone protease inhibitors | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| IN2014DN10386A (xx) | ||
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| EA201400246A1 (ru) | Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| IN2012DN06720A (xx) | ||
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| IN2015DN01164A (xx) | ||
| IN2015DN01165A (xx) | ||
| MX362489B (es) | Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa. | |
| IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| IN2015DN03921A (xx) | ||
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου | |
| EA201401309A1 (ru) | Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение | |
| IN2014MN02156A (xx) | ||
| EA201190282A1 (ru) | Фармацевтическая композиция, содержащая тамсулозин | |
| NZ701274A (en) | Oral b12 therapy | |
| TR201100151A2 (tr) | İbandronate formülasyonu. | |
| WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии |